CME Group Inc. (CME), headquartered in Chicago, Illinois, operates contract markets for the trading of futures and options on futures contracts. Valued at $94.3 billion by market cap, the company offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, and more. It facilitates trading on its trading floors, electronic platform, and through privately negotiated transactions that it clears.
Shares of this leading derivatives marketplace have underperformed the broader market over the past year. CME has declined 4.1% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 20.2%. In 2026, CME stock is down 3.8%, while SPX is up 13.2% on a YTD basis.
More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.
Narrowing the focus, CME has also lagged behind the iShares U.S. Broker-Dealers & Securities Exchanges ETF (IAI). The exchange-traded fund has gained about 7.2% over the past year. Moreover, the ETF’s 5.6% gains on a YTD basis outshine the stock’s losses over the same time frame.
www.barchart.com CME Group’s underperformance has been driven by a combination of operational cost pressures, competitive threats from alternative products like perpetual futures, and market uncertainty. These headwinds have been compounded by elevated operating expenses from technology investments, softer volumes in core interest rate contracts relative to prior peaks, and persistent insider selling.
On Jul. 22, CME shares closed up by 5% after reporting its Q2 results. Its adjusted EPS of $2.99 exceeded Wall Street expectations of $2.91. The company’s revenue was $1.71 billion, exceeding Wall Street forecasts of $1.68 billion.
For the current fiscal year, ending in December, analysts expect CME’s EPS to rise 9.6% to $12.27 on a diluted basis. The company’s earnings surprise history is mixed. It beat the consensus estimate in three of the last four quarters while missing the forecast on another occasion.
Among the 18 analysts covering CME stock, the consensus is a “Moderate Buy.” That’s based on six “Strong Buy” ratings, three “Moderate Buys,” six “Holds,” one “Moderate Sell,” and two “Strong Sells.”
www.barchart.com This configuration is more bullish than two months ago, with two analysts suggesting a “Moderate Buy.”
On Aug. 5, Barclays PLC (BCS) analyst Benjamin Budish maintained a “Hold” rating on CME and set a price target of $270, implying a potential upside of 3% from current levels.
The mean price target of $284.06 represents an 8.3% premium to CME’s current price levels. The Street-high price target of $330 suggests an upside potential of 25.9%.
On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
More news from Barchart
Ugly STMicroelectronics Stock May Have Just Signaled a Turnaround SoundHound AI's Acquisition Strategy Is Either Genius or Dangerous. How to Evaluate SOUN Stock. SpaceX Could Be Making $235 Billion From a Business It's Not Known For. SPCX Stock Investors Should Pay Attention. Dear Dell Stock Fans, Mark Your Calendars for September 3